started · updated
Atrys Health reports 9.7% revenue growth in first nine months of 2026
Atrys Health, a medical services company specializing in oncology, nuclear medicine, and diagnostic imaging, reported strong financial results for the first nine months of 2026. Revenue reached 117.1 million euros, a 9.7% increase compared to the same period in 2025. EBITDA rose by 18.5% to 14.2 million euros, representing a margin of 12.2%. When excluding accounting effects from R&D expense capitalization, organic EBITDA grew by 40.3%.
Operating cash flow increased by 152.6% to 11.3 million euros, driven by improved EBITDA and stricter investment discipline. The company also implemented a new organizational model that reduced personnel expenses by 15.1% and corporate operating expenses by 23.3%.
Key business segments included oncology, which saw a 22.5% revenue increase, and nuclear medicine, which saw a 10% revenue increase and a 157.4% EBITDA jump, bolstered by activity in Portugal. Internationally, Mexico showed significant growth with sales increasing by 131.9%. Following the sale of ASPY in January for 145 million euros, net financial debt was reduced to 37.5 million euros, a 78.1% decrease from the end of 2025.